GE HealthCare Technologies Inc.
GEHCGE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures contrast agents and radiopharmaceuticals.
Drugs in Pipeline
18
Phase 3 Programs
10
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 3 past
How GEHC's past catalysts played out
DatSCAN
Lewy Body Dementia
DaTSCAN™ Ioflupane (123I) Injection
Parkinsonian Syndrome
SPECT
Parkinson Disease
Sonazoid™
Liver Lesions
123I-mIBG (meta-iodobenzylguanidine)
Heart Failure, Congestive
Gadodiamide Injection
Aorto-iliac Stenosis
[18F] Flutemetamol
Normal Pressure Hydrocephalus
Flutemetamol (18F) Injection
Mild Cognitive Impairment
[18F]Flutemetamol
Alzheimer's Disease
PET MPI
Coronary Artery Disease (CAD)
GE-145 (AN113111) Injection
Healthy
GE-145
Chronic Renal Insufficiency
Regadenoson
Myocardial Ischemia
Ioforminol 160 mgI/mL
Healthy
Flurpiridaz (18F) Injection
Coronary Artery Disease (CAD)
Fluciclatide Injection
Solid Tumors
Fluciclatide Injection - (AH111585 (F18))
High-grade Glioma
AH110690 (18F) Injection
Alzheimer's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DatSCAN | Phase 3 | Lewy Body Dementia | - | - |
DaTSCAN™ Ioflupane (123I) Injection | Phase 3 | Parkinsonian Syndrome | - | - |
SPECT | Phase 3 | Parkinson Disease | - | - |
Sonazoid™ | Phase 3 | Liver Lesions | - | - |
123I-mIBG (meta-iodobenzylguanidine) | Phase 3 | Heart Failure, Congestive | - | - |
Gadodiamide Injection | Phase 3 | Aorto-iliac Stenosis | - | - |
[18F] Flutemetamol | Phase 3 | Normal Pressure Hydrocephalus | - | - |
Flutemetamol (18F) Injection | Phase 3 | Mild Cognitive Impairment | - | - |
[18F]Flutemetamol | Phase 3 | Alzheimer's Disease | - | - |
PET MPI | Phase 3 | Coronary Artery Disease (CAD) | - | - |
GE-145 (AN113111) Injection | Phase 2 | Healthy | - | - |
GE-145 | Phase 2 | Chronic Renal Insufficiency | - | - |
Regadenoson | Phase 2 | Myocardial Ischemia | - | - |
Ioforminol 160 mgI/mL | Phase 2 | Healthy | - | - |
Flurpiridaz (18F) Injection | Phase 2 | Coronary Artery Disease (CAD) | - | - |
Fluciclatide Injection | Phase 2 | Solid Tumors | - | - |
Fluciclatide Injection - (AH111585 (F18)) | Phase 2 | High-grade Glioma | - | - |
AH110690 (18F) Injection | Phase 2 | Alzheimer's Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in GE HealthCare Technologies Inc.'s drug pipeline?→
CatalystAlert tracks 18 drug candidates in GE HealthCare Technologies Inc.'s (GEHC) pipeline across Phase 3, Phase 2. Its lead program is DatSCAN (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GE HealthCare Technologies Inc.'s next FDA catalyst?→
GE HealthCare Technologies Inc.'s (GEHC) next tracked catalyst is a Earnings expected July 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GEHC biotech catalysts?→
Add GEHC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GE HealthCare Technologies Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.